spago cancer therapy
Spago Nanomedical's CEO: “huge commercial opportunities are unfolding”
Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of...
2023 springboard for Spago's radionuclide cancer therapy
In 2023, Swedish biotech Spago Nanomedical kicked off...
Spago's phase I/IIa cancer trial progressing steadily
The positive momentum for Spago Nanomedical carries over...
First patient dosed in Spago's phase I/IIa trial
Spago Nanomedical recently received approval to start the...
Notes
Senzime's partner receives FDA approval for TetraGraph module
Ellen sells the business for SEK 13,3 million
Oncopeptides increases sales in the second quarter
Alvotech acquires Ivers-Lee Group in Switzerland
OncoZenge enters into convertible loan with Linc
NEWSLETTER
NEWS
AlzeCure Pharma: “We have good momentum”
Modus Therapeutics CEO comments on latest milestone
The new era of weight loss: Does GLP-1 live up to expectations?
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The EU's new life science strategy – a step in the right direction or just fluff?
Early signs of spring in an otherwise frosty biotech landscape
